Introduction
Two proteins in serum, transcobalamins I and II (T.C. I and II), are implicated in the transport of vitamin B1,. In the fasting state T.C. I carries almost all of the vitamin B12 present in plasma. Vitamin B 12 entering the plasma is largely thought to be carried by the second binder, T.C. II. Hall and Finkler (1965) reported that after oral vitamin Bl, T.C. II was the first vitamin B12 binding protein to be labelled. The T.C. II and vitamin B 12 complex is rapidly cleared from plasma in a manner similar to haptoglobin (Hall and Finkler, 1965) , and in conjunction with the short half-life of the T.C. II and vitamin B,, complex it has been suggested that T.C. II is concerned primarily with transport of vitamin B12 from gut to tissues. There is a lag of several hours before vitamin B12 in the gut appears in blood, and a possible explanation is that the delay is due to the synthesis of carrier protein (?T.C. II) in the intestinal cells.
Under certain conditions a third protein in plasma showing different chromatographic behaviour from either T.C. I or T.C. II is demonstrable. Hom (1967) and Cooper (1969) Hall and Finkler (1967) in a patient with polycythaemia and a similar binder was also described by Carmel (1972) and Bloomfield and Scott (1972 (20 , j±g) was given by mouth to two volunteers over the age of 60. The procedure was explained and informed consent to the procedures given. Twenty-five ml of blood was obtained at the start of the procedure and at various times thereafter up to 48 hours. Plasma radioactivity was measured in all samples. Each plasma sample was concentrated twofold with an Amicon Diaflo ultrafilter before column chromatography.
T.C. I on the one hand and T.C. II and binder III on the other were separated on DEAE cellulose and the fractions containing T.C. II and binder III then placed on Sephadex G-200 (Bloomfield and Scott, 1972) to separate these two binders. Between 84% and 100% of the material put on the column was eluted from DEAE cellulose and between 56% and 96% from Sephadex G-200. (Figs. 1 and 2 ).
Results
No radioactivity was detected in plasma during the first two hours but was present at three hours. The distribution of the orally-administered dose among T.C. I, T.C. II, and binder III at this time is shown in the Thereafter the amount attached to these fractions increased and was still present at 48 hours (see Table) . Essentially similar results were obtained in both patients. J7ournal, 1972, 2, 442-443 Chronic mucocutaneous candidiasis without lethal immunological deficiencies is an infection with Candida albicans involving the skin, nails, scalp, and buccal and vaginal mucosa (Kirkpatrick et al., 1971) . Many of these patients exhibit anergy to intradermal challenge with extracts of candida, indicating a defect of cellular immunity against the organism, although humoral antibodies to the organism may be present (Turk, 1970; Chilgren et al., 1967) .
Of the several currently available approaches for reconstitution of cellular immune function the use of dialyzable transfer factor as described by Lawrence (1969) seems to be the most benign. The risk of graft-versus-host disease invariably accompanying bone marrow transplantation is avoided and sensitization to HL-A and other antigens is excluded, since transfer factor is dialyzable whereas tissue antigens are not (Lawrence, 1969 This report describes results of intensive therapy with transfer factor in a patient previously shown to be refractory to a small dose of this preparation (Rocklin et al., 1970) and to bone marrow transplantation (Meuwissen et al., 1971) . The patient, a 9-year-old white girl, was the subject of a previous report of defects of cellular immunity associated with chronic mucocutaneous candidiasis (Rocklin et al., 1970) . Skin sensitization for 2,4-dinitrofluorobenzene was attempted but challenge did not lead to a positive reaction. She had never reacted to candida extract skin tests with positive delayed hypersensitivity, there was no demonstrable release of migration inhibition factor by her lymphocytes in the presence of candida antigen, and the phytohaemagglutinin response of her lymphocytes was erratic (Rocklin et al., 1970) . Lymphopenia had been present since the age of 4j years, with total lymphocyte counts ranging from 400 to 1,000 cells/mm3. After her first presentation with severe cutaneous and oral moniliasis at 16 months of age several major therapeutic attempts were made. Amphotericin B 80 mg intravenously over six weeks was given at 16 months of age (body weight 8 kg). Transfer factor prepared from 3 ml of packed leucocytes was injected by Rocklin et al. (1970) at age 7 without indication of clinical or in-vitro lymphocytic improvement. One month later intravenous amphotericin B 330 mg was given over three weeks with definite signs of clearing of candida lesions.
Immediately after this last course a bone marrow transplant was undertaken in September 1969 with an HL-A non-identical sister as donor (Meuwissen et al., 1971) . Initial disappearance of candida infection after this combined treatment lasted four to six weeks. New candida lesions then appeared, and three months after the transplant a severe phase of cachexia began, characterized by diarrhoea, anorexia, raised liver enzymes, and splenomegaly, which was believed to be a graft-versus-host reaction (Meuwissen et al., 1971 
